3 years ago

Long-term risk of acute myocardial infarction, stroke and death with outpatient use of clarithromycin: a retrospective cohort study.

Rima Izem, Andrew D Mosholder, Esther H Zhou, David J Graham, Elizabeth M Kang, Mayurika Ghosh, Joo-Yeon Lee, Jacqueline M Major
This retrospective cohort study of subjects enrolled in the United Kingdom Clinical Practice Research Datalink from 2000-2013 evaluated long-term risks of death, stroke, and acute myocardial infarction (AMI) in adults prescribed clarithromycin. Subjects were outpatients aged 40-85 years prescribed clarithromycin, doxycycline, or erythromycin (287,748, 267,729, and 442,999 patients, respectively), or H. pylori eradication therapy with a proton pump inhibitor, amoxicillin, and either clarithromycin (27,639 patients) or metronidazole (14,863 patients). We analyzed time to death, stroke, or AMI with Cox proportional hazards regression. The long-term hazard ratio (HR) for death following one clarithromycin versus one doxycycline prescription was 1.29 (95% confidence interval (CI) 1.21, 1.25), increasing to 1.62 (95% CI 1.43, 1.84) for 5+ prescriptions of clarithromycin versus 5+ prescriptions for doxycycline. Erythromycin showed smaller risks versus doxycycline. Stroke and AMI were also increased after clarithromycin, but with smaller HRs than mortality. For H. pylori eradication, the HR for mortality following clarithromycin versus metronidazole regimens was 1.09 (95% CI 1.00, 1.18) overall, and was higher (1.65, 95% CI 0.88, 3.08) following 2+ prescriptions in subjects not on statins at baseline. Outpatient clarithromycin use was associated with long-term mortality increases, with evidence for a similar, smaller increase with erythromycin.

Publisher URL: http://doi.org/10.1093/aje/kwx319

DOI: 10.1093/aje/kwx319

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.